{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:37:49Z","timestamp":1792132669525,"version":"4.4.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"NIHR Clinical Lectureship","award":["CL-2019-16-001"],"award-info":[{"award-number":["CL-2019-16-001"]}]},{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"publisher","award":["NIHR303140"],"award-info":[{"award-number":["NIHR303140"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013986","name":"UK Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013986","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gilead UK & Ireland","award":["17437"],"award-info":[{"award-number":["17437"]}]},{"DOI":"10.13039\/100014461","name":"NIHR BRC","doi-asserted-by":"publisher","award":["203320"],"award-info":[{"award-number":["203320"]}],"id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Invasive candidiasis is a rising global health threat with increasing incidence, persistently high mortality, and diminishing treatment options. Antifungal resistance has rapidly emerged and spread, with multidrug-resistant species deemed an urgent and serious threat. While acknowledging the key role of antifungal stewardship and infection control in curbing spread, we examine the role of antifungal monotherapy in driving resistance and the potential for combination therapy to prevent stress adaptation and emergence of drug resistance. In addition to its role in mitigating resistance, combination treatment may improve drug penetration, expedite fungal clearance, and allow lower, less toxic doses of individual drugs to be used. A growing body of laboratory-based evidence suggests that antifungal combinations can yield synergistic activity against Candida spp., including against frequently multidrug-resistant Candida auris. It is imperative to test these combinations in clinical trials, incorporating resistance end points as a marker of success.<\/jats:p>","DOI":"10.1093\/ofid\/ofae072","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T08:58:36Z","timestamp":1708419516000},"source":"Crossref","is-referenced-by-count":28,"title":["Optimizing the Treatment of Invasive Candidiasis\u2014A Case for Combination Therapy"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3193-4888","authenticated-orcid":false,"given":"Rachel M","family":"Wake","sequence":"first","affiliation":[{"name":"Institute for Infection and Immunity, St George's University of London , London , UK"},{"name":"Clinical Academic Group, St George's Hospital NHS Trust , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phoebe E","family":"Allebone-Salt","sequence":"additional","affiliation":[{"name":"Institute for Infection and Immunity, St George's University of London , London , UK"},{"name":"Clinical Academic Group, St George's Hospital NHS Trust , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa L H","family":"John","sequence":"additional","affiliation":[{"name":"MRC Centre for Medical Mycology, University of Exeter , Exeter , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben A","family":"Caswall","sequence":"additional","affiliation":[{"name":"Institute for Infection and Immunity, St George's University of London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelesh P","family":"Govender","sequence":"additional","affiliation":[{"name":"Institute for Infection and Immunity, St George's University of London , London , UK"},{"name":"National Institute for Communicable Diseases, A Division of the National Health Laboratory Service , Johannesburg , South Africa"},{"name":"School of Pathology, University of Witwatersrand , Johannesburg , South Africa"},{"name":"Institute of Infectious Disease and Molecular Medicine, University of Cape Town , Cape Town , South Africa"},{"name":"MRC Centre for Medical Mycology, University of Exeter , Exeter , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronen","family":"Ben-Ami","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Tel-Aviv Sourasky Medical Center, and the Sackler , Tel-Aviv , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyle W","family":"Murray","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of the Witwatersrand , Johannesburg , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Logan","sequence":"additional","affiliation":[{"name":"Institute for Infection and Immunity, St George's University of London , London , UK"},{"name":"Clinical Academic Group, St George's Hospital NHS Trust , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S","family":"Harrison","sequence":"additional","affiliation":[{"name":"Institute for Infection and Immunity, St George's University of London , London , UK"},{"name":"Clinical Academic Group, St George's Hospital NHS Trust , London , UK"},{"name":"MRC Centre for Medical Mycology, University of Exeter , Exeter , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tihana A","family":"Bicanic","sequence":"additional","affiliation":[{"name":"Institute for Infection and Immunity, St George's University of London , London , UK"},{"name":"Clinical Academic Group, St George's Hospital NHS Trust , London , UK"},{"name":"MRC Centre for Medical Mycology, University of Exeter , Exeter , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"2024061711532401400_ofae072-B1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/jof4030097","article-title":"Treatment of invasive candidiasis: a narrative review","volume":"4","author":"Ben-Ami","year":"2018","journal-title":"J Fungi (Basel)"},{"key":"2024061711532401400_ofae072-B2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024061711532401400_ofae072-B3","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1038\/s41467-022-32249-5","article-title":"The importance of antimicrobial resistance in medical mycology","volume":"13","author":"Gow","year":"2022","journal-title":"Nat Commun"},{"key":"2024061711532401400_ofae072-B4","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1093\/ofid\/ofy358","article-title":"Twenty years of the SENTRY antifungal surveillance program: results for Candida species from 1997\u20132016","volume":"6","author":"Pfaller","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2024061711532401400_ofae072-B5","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1016\/S2666-5247(23)00067-8","article-title":"Worldwide emergence of fluconazole-resistant Candida parapsilosis: current framework and future research roadmap","volume":"4","author":"Daneshnia","year":"2023","journal-title":"Lancet Microbe"},{"key":"2024061711532401400_ofae072-B6","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3390\/tropicalmed7080188","article-title":"Global prevalence of antifungal-resistant Candida parapsilosis: a systematic review and meta-analysis","volume":"7","author":"Yamin","year":"2022","journal-title":"Trop Med Infect Dis"},{"key":"2024061711532401400_ofae072-B7","author":"Center for Healthcare-Acquired Respiratory Infections and Mycology (CHARM)"},{"key":"2024061711532401400_ofae072-B8","doi-asserted-by":"crossref","first-page":"103243","DOI":"10.1016\/j.fgb.2019.103243","article-title":"Candida auris and multidrug resistance: defining the new normal","volume":"131","author":"Lockhart","year":"2019","journal-title":"Fungal Genet Biol"},{"key":"2024061711532401400_ofae072-B9","doi-asserted-by":"crossref","first-page":"e00458-19","DOI":"10.1128\/mSphere.00458-19","article-title":"Combined antifungal resistance and biofilm tolerance: the global threat of Candida auris","volume":"4","author":"Kean","year":"2019","journal-title":"mSphere"},{"key":"2024061711532401400_ofae072-B10","doi-asserted-by":"crossref","first-page":"489","DOI":"10.7326\/M22-3469","article-title":"Worsening spread of Candida auris in the United States, 2019 to 2021","volume":"176","author":"Lyman","year":"2023","journal-title":"Ann Intern Med"},{"key":"2024061711532401400_ofae072-B11","doi-asserted-by":"crossref","first-page":"e00053-22","DOI":"10.1128\/aac.00053-22","article-title":"Candida auris pan-drug-resistant to four classes of antifungal agents","volume":"66","author":"Jacobs","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2024061711532401400_ofae072-B12","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.3201\/eid2907.221888","article-title":"Nationwide outbreak of Candida auris infections driven by COVID-19 hospitalizations, Israel, 2021\u201320221","volume":"29","author":"Biran","year":"2023","journal-title":"Emerg Infect Dis"},{"key":"2024061711532401400_ofae072-B13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3390\/healthcare11030425","article-title":"Candida auris as an emergent public health problem: a current update on European outbreaks and cases","volume":"11","author":"Geremia","year":"2023","journal-title":"Healthcare"},{"key":"2024061711532401400_ofae072-B14","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1128\/AAC.01763-15","article-title":"Posttreatment antifungal resistance among colonizing Candida isolates in candidemia patients: results from a systematic multicenter study","volume":"60","author":"Jensen","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2024061711532401400_ofae072-B15","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1128\/AAC.01128-10","article-title":"Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients","volume":"55","author":"Lortholary","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2024061711532401400_ofae072-B16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41579-019-0322-2","article-title":"Drug resistance and tolerance in fungi","volume":"18","author":"Berman","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"2024061711532401400_ofae072-B17","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.3201\/eid2509.190040","article-title":"Epidemiologic shift in candidemia driven by Candida auris, South Africa, 2016\u20132017","volume":"25","author":"van Schalkwyk","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"2024061711532401400_ofae072-B18","author":"Allebone-Salt"},{"key":"2024061711532401400_ofae072-B19","doi-asserted-by":"crossref","first-page":"e00655-16","DOI":"10.1128\/mBio.00655-16","article-title":"Heteroresistance to fluconazole is a continuously distributed phenotype among Candida glabrata clinical strains associated with in vivo persistence","volume":"7","author":"Ben-Ami","year":"2016","journal-title":"mBio"},{"key":"2024061711532401400_ofae072-B20","author":"Caswall"},{"key":"2024061711532401400_ofae072-B21","author":"Zhai"},{"key":"2024061711532401400_ofae072-B22","doi-asserted-by":"crossref","first-page":"e02195-19","DOI":"10.1128\/AAC.02195-19","article-title":"In vitro evaluation of antifungal drug combinations against multidrug-resistant Candida auris isolates from New York outbreak","volume":"64","author":"O\u2019Brien","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2024061711532401400_ofae072-B23","doi-asserted-by":"crossref","first-page":"e01393-19","DOI":"10.1128\/AAC.01393-19","article-title":"In vitro antifungal combination of flucytosine with amphotericin B, voriconazole, or micafungin against Candida auris shows no antagonism","volume":"63","author":"Bidaud","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2024061711532401400_ofae072-B24","doi-asserted-by":"crossref","first-page":"e01645-22","DOI":"10.1128\/aac.01645-22","article-title":"Heightened efficacy of anidulafungin when used in combination with manogepix or 5-flucytosine against Candida auris in vitro","volume":"67","author":"John","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2024061711532401400_ofae072-B25","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/jac\/dkl395","article-title":"Combined antifungal therapy in a murine infection by Candida glabrata","volume":"58","author":"Marine","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2024061711532401400_ofae072-B26","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/jac\/46.2.171","article-title":"Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions","volume":"46","author":"Vermes","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"2024061711532401400_ofae072-B27","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1172\/JCI124516","article-title":"Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis","volume":"129","author":"Stone","year":"2019","journal-title":"J Clin Invest"},{"key":"2024061711532401400_ofae072-B28","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin","volume":"81","author":"Hoenigl","year":"2021","journal-title":"Drugs"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofae072\/56742232\/ofae072.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/6\/ofae072\/58234324\/ofae072.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/6\/ofae072\/58234324\/ofae072.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T07:54:20Z","timestamp":1718610860000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae072\/7612672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae072","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,2,22]]},"article-number":"ofae072"}}